Sort
10,766 grants matching “checkpoint inhibitor”
Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer
$483,395Joseph Nicholas Bodor · Research Inst Of Fox Chase Can Ctr · R21 · FY2024 · CA
Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer
$483,360J. Silvio Gutkind · University Of California, San Diego · R01 · FY2025 · DE
INTERACITONS OF HPV ONCOGENES WITH THE P53 PATHWAY
$483,052Fred Hutchinson Cancer Research Center · R01 · FY2003 · CA
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer
$482,771Jean Zhao · Dana-Farber Cancer Inst · P01 · FY2025 · CA
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
$482,274Charles L Sawyers · Columbia University Health Sciences · P01 · FY2024 · CA
AHR-mediated immunosuppression in glioblastoma
$482,198Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2020 · ES
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$482,163Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2021 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$482,114Periasamy Selvaraj · Emory University · R01 · FY2017 · CA
Understanding the impact of chemotherapy on breast cancer metastasis and immune function in the liver
$481,921Sandra S McAllister · Brigham And Women'S Hospital · R01 · FY2025 · CA
Renalase inhibition for treatment of unresectable melanoma
$481,894Harriet M Kluger · Yale University · R01 · FY2020 · CA
PKCdelta and salivary gland radioprotection
$481,884Mary Elaine Reyland · University Of Colorado Denver · R01 · FY2020 · DE
PKCdelta and salivary gland radioprotection
$481,884Mary Elaine Reyland · University Of Colorado Denver · R01 · FY2019 · DE
PKCdelta and salivary gland radioprotection
$481,884Mary Elaine Reyland · University Of Colorado Denver · R01 · FY2021 · DE
Breaking down tumor immune privilege through targeted hypoxia reduction
$481,691Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Breaking down tumor immune privilege through targeted hypoxia reduction
$481,691Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma
$481,659Cassian Yee · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$481,578Seth M Pollack · Northwestern University At Chicago · R01 · FY2023 · CA
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
$481,567Jennifer Temel · Massachusetts General Hospital · R01 · FY2021 · CA
Renalase inhibition for treatment of unresectable melanoma
$481,477Harriet M Kluger · Yale University · R01 · FY2021 · CA
TIGIT in acute kidney injury and repair
$481,466Sanjeev Noel · Johns Hopkins University · R01 · FY2024 · DK
PAIRS: Validating telomerase reverse transcriptase (TERT) as an intrinsic vulnerability toward sensitizing cancer to radiation
$481,444Stephen J. Kron · University Of Chicago · R01 · FY2025 · CA
Novel DNA damage response therapeutics targeting replication protein A
$481,424John J Turchi · Indiana University Indianapolis · R01 · FY2023 · CA
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
$481,288Iman Osman · New York University School Of Medicine · R01 · FY2018 · CA
Developing newly combined therapeutic strategies for mature B cell lymphoma
$480,946Jing Hong Wang · University Of Colorado Denver · R01 · FY2019 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$480,895Periasamy Selvaraj · Emory University · R01 · FY2020 · CA